Eli Lilly Q1 2026 Earnings Preview: Can the Pharma Giant Sustain Its Growth Momentum?

Eli Lilly prepares to unveil its Q1 2026 earnings Thursday before market open, with analysts anticipating a 36.8% year-on-year revenue surge. The pharmaceutical behemoth posted $19.29 billion in revenue last quarter—a 42.6% annual jump—outpacing expectations and raising full-year guidance. While growth may decelerate slightly from the 45.2% recorded in the year-ago quarter, Lilly’s trajectory remains formidable by industry standards.

Wall Street’s optimism shows in upwardly revised estimates over the past month, though the company has stumbled against forecasts before. As the first major pharma firm to report this season, Lilly’s results will set the tone for sector performance. Notably, its shares have dipped 1.5% over the last 30 days while peers gained 10.8% on average—a divergence that heightens scrutiny on this earnings release.